Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating)’s stock price reached a new 52-week high on Thursday following a stronger than expected earnings report. The company traded as high as $14.51 and last traded at $14.47, with a volume of 4576 shares changing hands. The stock had previously closed at $13.57.
The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.05. The firm had revenue of $32.49 million during the quarter, compared to analysts’ expectations of $30.11 million. Deciphera Pharmaceuticals had a negative net margin of 231.99% and a negative return on equity of 79.39%. Deciphera Pharmaceuticals’s revenue for the quarter was up 37.8% on a year-over-year basis. During the same period in the prior year, the company posted ($1.21) earnings per share.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on the stock. HC Wainwright upped their price objective on shares of Deciphera Pharmaceuticals from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Friday. JMP Securities upgraded shares of Deciphera Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $23.00 price target for the company in a report on Friday. Finally, SVB Leerink upped their price target on shares of Deciphera Pharmaceuticals from $15.00 to $21.00 and gave the company an “outperform” rating in a report on Friday. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $14.13.
Institutional Inflows and Outflows
Deciphera Pharmaceuticals Trading Down 1.8 %
The stock’s 50-day moving average price is $12.77 and its 200 day moving average price is $10.49.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
- Get a free copy of the StockNews.com research report on Deciphera Pharmaceuticals (DCPH)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.